Copyright 2002 eMediaMillWorks, Inc.
(f/k/a Federal
Document Clearing House, Inc.)
Federal Document Clearing House
Congressional Testimony
March 5, 2002 Tuesday
SECTION: CAPITOL HILL HEARING TESTIMONY
LENGTH: 1634 words
COMMITTEE:
SENATE HEALTH, EDUCATION, LABOR AND PENSIONS
HEADLINE: HUMAN CLONING
TESTIMONY-BY: PAUL BERG ROBERT AND VIVIAN CAHILL,
PROFESSOR OF CANCER RESEARCH AND BIOCHEMISTRY, EMERITUS DIRECTOR OF THE
AFFILIATION: BECKMAN CENTER FOR MOLECULAR AND GENETIC
MEDICINE, EMERITUS
BODY: Statement of
Paul
Berg Robert and Vivian Cahill Professor of Cancer Research and Biochemistry,
Emeritus Director of the Beckman Center for Molecular and Genetic Medicine,
Emeritus
Stanford University Medical Center, Stanford, California Chair,
Public Policy Committee, The American Society for Cell Biology
Mr.
Chairman, Members of the Committee, thank you for inviting me to testify before
you on this most important issue. I have followed the debate on the cloning
questions we will address today and I welcome the opportunity to weigh in with
my own views on the matter. It is also a distinct privilege to join Mr. Reeve,
who has been such an articulate spokesman for support of research that could
contribute therapies and cures for debilitating diseases, spinal cord injury
being a most personal issue.
For the record, I am Paul Berg, Robert and
Vivian Cahill Professor of Cancer Research and Biochemistry, Emeritus and
Director of the Beckman Center for Molecular and Genetic Medicine, Emeritus at
Stanford University Medical Center. I am also Chairman of the American Society
of Cell Biology Public Policy Committee. For my work in developing recombinant
DNA technology, I received the Nobel Prize in Chemistry in 1980. The specter of
cloning generated by films and novels has obscured the role and importance of
the process in some of the most important recent advances in biomedical
research. Cloning is a scientific term to describe the preparation of an
"infinite" number of copies of, for example, a single molecule, cell, virus or
bacterium. For example, cloning DNA molecules was essential for solving the
human genome sequence. Similarly, cloning DNA is critical to fight against
bioterrorism and has already been used in the determination of the entire genome
sequences of several organisms identified as bioweapons. Furthermore, cloning is
integral to modern forensic procedures, medical diagnostics, vaccine
development, and the discovery and production of many of the most promising
drugs. Cloning is also used to make genetically identical plants and livestock
enabling continued agricultural breakthroughs necessary to feed a rapidly
growing and undernourished world population. I regret greatly that the
frightening thoughts conjured up by the term alone have clouded the issues that
confront us.
That said, very few, if any, reputable biomedical
scientists condone attempts to produce a cloned human being. In the words of the
distinguished National Academy of Sciences Panel that considered this issue, "it
is dangerous and likely to fail"; in short, there are unacceptable risks to the
mother and any fetus that would result from the procedure. Moreover, there is no
compelling reason today or perhaps in the immediate future to attempt such a
procedure. Therefore, I support the portion of Senator Brownback's bill (S-790)
that mandates a legally enforceable ban on reproductive cloning. However, I am
loath to permit the possibility that this mode of reproduction would remain for
all time an anathema. I would advocate that the legislation establish a
mechanism for reviewing the statute periodically, perhaps every ten years, to
determine if the judgements made today remain valid in the light of new
scientific information.
But Senator Brownback's proposed legislation
goes far beyond a prohibition of reproductive cloning. His bill also includes
two provisions that would deprive American patients access to potential
therapies for some of the most debilitating diseases. The first of these would
impose criminal penalties and heavy fines on scientists who attempt to
transplant the nucleus from a normal body cell into a human egg cell whose own
nucleus had been removed. The power of this procedure is that such an asexually
produced product can be nurtured to divide a sufficient number of times to
produce a ball of cells within which embryonic stem cells reside. These cells
can be propagated in Petri dishes indefinitely all the while retaining their
capacity to be coaxed into forming any of the body's many cell types. The
particular value of nuclear transplantation technology is that the embryonic
stem cells and the differentiated cells and tissues they yield have the same
genetic makeup as the individual that donated the nucleus. Consequently, they
can be used to repair or replace damaged or diseased tissues without invoking
immune rejection that would occur with unmatched cells. In a sense, a person's
own DNA is used to create compatible cells for the treatment of, for example,
that individual's cancer, diabetes, spinal cord injury or Parkinson's disease.
A particularly promising opportunity that is also foreclosed by the
Brownback bill is the preparation of stem cells using body cell nuclei from
individuals with inherited mutations; particularly, ones that predispose such
individuals to an increased probability for developing a variety of life-
threatening and debilitating illnesses late in life: for example, breast, colon,
prostate and other cancers, as well as heart, neurological and autoimmune
diseases. Such currently unavailable stem cell lines would provide a new way to
explore how these life- threatening, late-onset diseases develop and possibly
generate clues to their prevention or cure. Such studies might help illuminate
the interrelations among inheritance, environment and chance that govern so much
of the balance between health and disease.
Senator Brownback has been
outspoken in his belief that experimentation with embryonic stem cells for
therapeutic purposes is unnecessary. He believes that we already have the means
to meet that challenge by using adult-derived stem cells, specialized cells that
already exist in many of our tissues and are capable of repairing damaged or
diseased tissue. Unfortunately, Senator Brownback has relied on claims that are
largely anecdotal, most often unreplicated by others and, in some cases,
experiments that are demonstrably flawed. While some adult- derived stem cells
undoubtedly hold promise for certain therapies, e.g., bone marrow
reconstitution, repair of damaged heart muscle, liver and neural tissues, their
potential is limited by their rarity and the consequent difficulty of harvesting
and propagating them in quantities sufficient to be useful. Furthermore, their
developmental potential is limited compared to the multi-potentiality of
embryonic stem cells. Every scientific review of the therapeutic opportunities
afforded by adult-derived and embryonic stem cells has concluded that embryonic
stem cells are far more versatile for medical therapies. Nevertheless,
scientists working in these fields recommend strongly, as do I, that research
should proceed vigorously with both adult and embryonic cells so as not to delay
or forgo reaping their benefits for patients as soon as possible.
One of
the concerns that has been cited as justification for the criminalization of the
nuclear transplantation procedure is to guard against rogue attempts to implant
the product into a woman's uterus for the purpose of creating a cloned child.
But surely we have other means for preventing that very unlikely possibility.
You may recall, Senator Kennedy, that 25 years ago, in response to widespread
concerns about the possible dangers of recombinant DNA research, the U.S. Senate
came close to imposing severe criminal penalties on such research and
development in this country. Had that occurred, it would have cost us our nation
its scientific eminence and the world's leading biotechnology industry.
Fortunately, another means was adopted to ensure that the work could be done
safely. That included regulation, which mandated oversight by an institutional
review process and approval by a National Institutes of Health Recombinant DNA
Advisory Committee before such research could be undertaken. Once approved, the
Committee monitored the research's progress to ensure compliance with governing
regulations. A process resembling the one I outlined or the one that was
instituted to oversee gene therapy experimentation could be implemented to
ensure that nuclear transplantation technology is done only to advance medical
knowledge and develop medical therapies, and not for procreation. Appropriate
penalties could certainly be levied on individuals or organizations for gross
infractions or deliberate violations of the prescribed procedures.
The
third provision in the Brownback bill, which has escaped close scrutiny in the
public debate, is one I find particularly onerous. The bill mandates the same
severe criminal penalties on those who import into the United States materials
or medical treatments that were developed using the nuclear transplantation
technology. It seems unbelievable to me that the United States Senate would deny
physicians or their patients from access to the most advanced therapies. It
would appear, therefore, that millions of suffering Americans would be denied
hope of cures for their disabilities because certain members of our Congress
possess an aversion, admittedly deeply felt, to a procedure that was used in its
development. Surely we must concede that all of us have a responsibility to
those suffering from life-threatening diseases and severe handicaps to explore
every opportunity and every means to alleviate their suffering.
We take
considerable pride in being a pluralistic society. So, there must be ample room
for differences concerning the moral and ethical interpretations of early and
intermediate stages of human development, especially where acknowledging these
alternate and equally legitimate views can mean the difference between life and
death for many of our citizens.
Thank you for the opportunity to express
my views. I am ready to respond to the committee's questions.
LOAD-DATE: March 7, 2002